AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05848440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9550
Description: Participants will be administered AZD9550 intravenously.
Study NCT05848440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered matching volumes of placebo subcutaneously or intravenously.
Study NCT05210049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Esocheck/Esoguard
Description: All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
Study NCT06556784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week at-home immersive virtual reality exergame
Description: 12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
Study NCT04359108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation System for Users of a Visual Prosthesis
Description: We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found. We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.
Study NCT05542199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent nutrition supplement (MCNS)
Description: Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
Study NCT05061524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35324
Description: Subcutaneous injection of YH35324
Study NCT05061524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of None of active ingredient
Study NCT05061524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection of Omalizumab
Study NCT06371352 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
Study NCT04631549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: SHR3680, PO, single dose
Study NCT04692714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee prosthesis implementation with additional cement
Description: During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot with additional cement.
Study NCT04692714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee prosthesis implementation without additional cement
Description: During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot without additional cement.
Study NCT06693128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg
Study NCT06693128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Oxaliplatin
Description: S-1, Oxaliplatin, q3w
Study NCT06692309 — intervention group
Intervention type: PROCEDURE
Intervention: cardiovascular surgery
Description: Heart bypass surgery; Heart valve replacement surgery
Study NCT06693271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intervention of protein, blueberries
Description: intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day.
Study NCT06693271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.
Study NCT06631833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention measures based on the YPAP model.
Description: The intervention group received an 8-week intervention program aimed at gradually increasing their physical activity levels. The intervention program included the following components: 1) 1-2 sessions of moderate-intensity physical activity per week, each lasting 45 minutes, with activities provided by physical activity experts; 2) one health education lecture every two weeks, each lasting 60 minutes; and 3) one family physical activity session per week, each lasting 30 minutes at a lower intensity. At the end of the intervention period, relevant questionnaires were used for measurement.
Study NCT05448755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
Study NCT06693713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Youth Series
Description: The Mental Health Youth Series is an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics. The intervention package includes a facilitation guide and a guide for parents and caregivers. The program is intended to be conducted by an experienced facilitator, although there is no specific training provided for facilitators outside of the facilitation guide.
Study NCT06692101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral care
Description: We prepared the necessary tools and suction devices, then helped patients sit upright before starting oral care. Using a flashlight and toothbrush, we assessed the mouth and removed any food debris, aspirating saliva if needed. We cleaned the teeth using a toothbrush, dental floss, and an interdental brush with a small amount of fluoridated toothpaste. The Bass method was used for brushing. Finally, we cleaned the front two-thirds of the tongue with a damp toothbrush.
Study NCT06692101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: We used the VitalStim® device to deliver neuromuscular electrical stimulation (NMES). Before placing the electrodes, participants were asked to shave any facial hair and clean their neck skin with alcohol wipes. We positioned four electrode pads horizontally, above and below the hyoid bone. The device provided stimulation at a pulse rate of 80 Hz with a biphasic pulse duration of 300 microseconds. Each session lasted 30 minutes, with the intensity gradually increased in 0.5 mA intervals, based on the patient's comfort level, and adjusted to their maximum tolerance.
Study NCT06692933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol in the form of hemp
Description: Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel
Study NCT04904913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.
Study NCT04904913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously (SC) once a week.
Study NCT06289764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot Essential Oil
Description: Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
Study NCT06289764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit Essential Oil
Description: Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
Study NCT06289764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sweet almond oil
Description: Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles
Study NCT05805189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein (PV) isolation
Description: The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
Study NCT05805189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein (PV) isolation
Description: The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
Study NCT05312658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External aortic compression
Description: External aortic compression by assistant in cesarean section.
Study NCT06275074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
Study NCT06275074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
Study NCT06275074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
Study NCT05010005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 20mg BID
Study NCT05010005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib 25mg, 50mg, or 75mg BID
Study NCT05269082 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study NCT05359562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure & Response Prevention (EX/RP)
Description: Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
Study NCT05359562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure & Response Prevention (EX/RP)
Description: Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
Study NCT04416724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Lens removal by Phacoemulsification
Study NCT04416724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: Laser application in trabecular meshwork
Study NCT04817436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program (APA)
Description: adapted physical activity program (APA)
Study NCT04817436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity program (APA)
Description: adapted physical activity program (APA)
Study NCT05078437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Description: The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
Study NCT05116345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXTENZA
Description: Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
Study NCT05116345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Dexamethasone
Description: topical dexamethasone drops
Study NCT06083714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization Exercises
Description: Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
Study NCT06570174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral protein supplements
Description: Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.
Study NCT06570174 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
Study NCT06557811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
Study NCT06475300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06475300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT05860244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol for 6 months
Study NCT05860244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Syrup for 6 months
Study NCT06564688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Swallowing function test
Description: The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants.
Study NCT05724771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)
Description: OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
Study NCT06563687 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom ONE+
Description: In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
Study NCT06563687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom ONE+
Description: In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
Study NCT05866640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2 filter and delivery system
Description: Placement of F2 device in aorta to cover great cerebral vessels
Study NCT05177380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation program of facial involvement in systemic sclerosis
Description: Personalized rehabilitation program of facial involvement in systemic sclerosis
Study NCT05177380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delivery of a standard prescription for facial rehabilitation
Description: Delivery of a standard prescription for facial rehabilitation
Study NCT04831229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform activities on interactive tablet
Description: AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
Study NCT04831229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform passive on interactive tablet
Description: The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions.
Study NCT05501899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
Study NCT06083714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercises
Description: It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
Study NCT06083714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Schroth Exercises
Description: It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
Study NCT05904262 — intervention group
Intervention type: OTHER
Intervention: Foot Sole Sensation Evaluation
Description: Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
Study NCT06148662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention (negative control)
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.
Study NCT06148662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water (positive control)
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds.
Study NCT06148662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental foam Biorepair PERIBIOMA
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.
Study NCT06148662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental foam WATER:DENT
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.
Study NCT06148662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental spray BUCCOTHERM
Description: The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam.